Search results
Showing 181 to 195 of 214 results for arthritis
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA711)
This guidance has been updated and replaced by NICE technology appraisal guidance TA815.
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
Discontinued Reference number: GID-HST10007
NICE has developed a Medtech Innovation Briefing (MIB) on the OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic
Discontinued Reference number: GID-TA10310
Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.
This guidance has been updated and replaced by NICE guideline NG219.
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
Robot-assisted surgery for orthopaedic procedures: early value assessment (HTE22)
Early value assessment (EVA) guidance on robot-assisted surgery for orthopaedic procedures....
View recommendations for HTE22Show all sections
Agenda and papers of the NICE public board meeting on 19 January 2022
This guidance has been updated and replaced by NICE technology appraisal guidance 280.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures....
In development Reference number: GID-TA11352 Expected publication date: TBC
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.